NATCO Pharma Ltd.
NATCOPHARM · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹1,668.72. Low-confidence estimate — limited data.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%16.9%
- ✓Low debt (D/E < 0.5)0.08x
- ✓Positive free cash flow
- ✕Revenue growth > 10%-40%
- ✕Earnings growing-34%
- ✓Net margin ≥ 10%34.8%
- ✓Current ratio > 1.53.01
- ✓Below our fair value
- ✓Margin of safety ≥ 20%
- ✕Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 6.44
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Healthy profit margin (34.8%).
- •Financially solid — Altman Z 6.44.
Weaknesses
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Trading in our value buy zone versus sector peers.
- •Trades ~146% below our estimated fair value.
Threats
- •Earnings contracting year on year.
About NATCO Pharma Ltd.
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain man
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.